Results of Capital Raise

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com






FOR PUBLIC RELEASE


NZX Limited
Wellington

20 October 2026


Rua Bioscience Rights Offer raises approximately $1.0 million

Rua Bioscience Limited (NZX: RUA) confirms that its 1 for 3 renounceable Rights Offer, at
an issue price of $0.025 per new share, closed on 15 October 2026, raising approximately
$1.0 million.
The amount raised comprises entitlements and oversubscriptions taken up by existing
shareholders. Eligible shareholders subscribed for 39,648,249 new shares, including
oversubscriptions which is approximately 12% of the existing shares.
Rua will now allow applications for the remaining shortfall shares in accordance with
NZX Listing Rule 4.4.
The allotment and issue of, and trading in, new shares under the Rights Offer is expected
to occur on Wednesday 21 October 2026.
Rua Bioscience Chair Anna Stove said: “On behalf of the Board and the Rua Bioscience
team, I want to thank the shareholders who participated in the Rights Offer. The
approximately $1.0 million raised provides additional capital to support Rua’s growth,
but is below the $2.8 million sought and does not fully meet the company’s working
capital requirements.”
“Rua has a significant commercial opportunity ahead. Our UK sales and distribution
agreement is expected to generate more than NZ$10 million in revenue over a two-year
term. It is our largest export agreement to date and a significant milestone for a
company of Rua’s size, demonstrating the potential of our export-led, capital-light
model.”
MARKET UPDATE

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
“Delivering on this opportunity requires us to fund inventory and working capital ahead
of sales. Our principal constraint is working capital, not infrastructure. The Board remains
confident that Rua can secure the additional capital required. We are in discussions with
existing shareholders who wanted to see the Rights Offer outcome before considering
further commitments. Subject to shareholder approval at the ASM, placement capacity
would provide another funding option. We are also pursuing options to realise value
from the Gisborne manufacturing facility.”

ENDS  
 

The person who authorised this announcement:

Paul Naske
Chief Executive Officer
paul.naske@ruabio.com
+64 21 445154